Today's The Hindu editorials focus on two critical issues: the growing duopoly in India's UPI ecosystem and the dangers of poorly manufactured drugs. The first editorial highlights the dominance of PhonePe and Google Pay, warning about reduced competition, systemic risks, and limited consumer choice, and calls for regulatory measures to ensure fair competition and innovation. The second editorial discusses the health risks posed by substandard drugs, inadequate regulatory oversight, and inconsistent inspections. It emphasizes the need for stringent quality controls, strict penalties, and public awareness to safeguard public health and improve India's pharmaceutical sector. Both issues demand urgent attention.